133 related articles for article (PubMed ID: 10684712)
21. Familial papillary serous carcinoma of the cervix, peritoneum, and ovary: a report of the first case.
Kaplan EJ; Caputo TA; Shen PU; Sassoon RI; Soslow RA
Gynecol Oncol; 1998 Aug; 70(2):289-94. PubMed ID: 9740708
[TBL] [Abstract][Full Text] [Related]
22. Decreased expression of RIZ1 and its clinicopathological significance in epithelial ovarian carcinoma: correlation with epigenetic inactivation by aberrant DNA methylation.
Akahira J; Suzuki F; Suzuki T; Miura I; Kamogawa N; Miki Y; Ito K; Yaegashi N; Sasano H
Pathol Int; 2007 Nov; 57(11):725-33. PubMed ID: 17922684
[TBL] [Abstract][Full Text] [Related]
23. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
[TBL] [Abstract][Full Text] [Related]
24. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum.
Hashi A; Yuminamochi T; Murata S; Iwamoto H; Honda T; Hoshi K
Int J Gynecol Pathol; 2003 Oct; 22(4):374-7. PubMed ID: 14501819
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
[TBL] [Abstract][Full Text] [Related]
26. Advanced ovarian carcinoma: molecular evidence of unifocal origin.
Li S; Han H; Resnik E; Carcangiu ML; Schwartz PE; Yang-Feng TL
Gynecol Oncol; 1993 Oct; 51(1):21-5. PubMed ID: 8244169
[TBL] [Abstract][Full Text] [Related]
27. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.
Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ
Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402
[TBL] [Abstract][Full Text] [Related]
28. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
[TBL] [Abstract][Full Text] [Related]
29. Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer.
Cvetković D; Williams SJ; Hamilton TC
Clin Cancer Res; 2003 Mar; 9(3):1013-20. PubMed ID: 12631600
[TBL] [Abstract][Full Text] [Related]
30. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
[TBL] [Abstract][Full Text] [Related]
31. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity of WT1 gene in the prognosis of sporadic Wilms' tumour in children.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Anticancer Res; 1999; 19(2B):1451-4. PubMed ID: 10365122
[TBL] [Abstract][Full Text] [Related]
33. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K
J Surg Oncol; 2006 Apr; 93(5):379-86. PubMed ID: 16550573
[TBL] [Abstract][Full Text] [Related]
34. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.
Dupont J; Wang X; Marshall DS; Leitao M; Hedvat CV; Hummer A; Thaler H; O'Reilly RJ; Soslow RA
Gynecol Oncol; 2004 Aug; 94(2):449-55. PubMed ID: 15297187
[TBL] [Abstract][Full Text] [Related]
35. Isolation and preliminary characterization of an ovarian carcinoma cell line from a patient with familial ovarian cancer.
Buller RE; Niemann T; Connor JP; Squatrito RC; Skilling JS; Anderson B
Gynecol Oncol; 1995 Jan; 56(1):39-44. PubMed ID: 7821846
[TBL] [Abstract][Full Text] [Related]
36. Microdissection-based mutational genotyping of serous borderline tumors of the ovary.
Krishnamurti U; Sasatomi E; Swalsky PA; Jones MW; Finkelstein SD
Int J Gynecol Pathol; 2005 Jan; 24(1):56-61. PubMed ID: 15626917
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps.
Euscher ED; Malpica A; Deavers MT; Silva EG
Am J Surg Pathol; 2005 Aug; 29(8):1074-8. PubMed ID: 16006803
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
39. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary.
Bruening W; Giasson BI; Klein-Szanto AJ; Lee VM; Trojanowski JQ; Godwin AK
Cancer; 2000 May; 88(9):2154-63. PubMed ID: 10813729
[TBL] [Abstract][Full Text] [Related]
40. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Yamada H; Yamamoto R; Sakuragi N; Enokida H; Verma M; Dahiya R
Cancer; 2005 Nov; 104(9):1924-30. PubMed ID: 16134181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
